Compartment Syndrome of LegPhase 4CECSNCT05466539
Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A
A Phase 4 study testing AbobotulinumtoxinA in people with Compartment Syndrome of Leg, run by Emory University at 2 sites in United States.
Trial summary
Chronic Exertional Compartment Syndrome (CECS) is a painful condition affecting runners and it is caused by a reversible increase in pressure within a closed compartment in the leg. Currently, to diagnose CECS, a large needle is placed into the muscle to measure pressure, which is invasive and painful. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Compartment Syndrome of Leg
- What is being tested?
- AbobotulinumtoxinA
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 3 participants
- Where
- 2 sitesUnited States
- Study dates
- 25 Apr 2024to 13 Aug 2025
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult male and female runners aged 18-65 years
- Group providing normative values for SWE and needle manometry - ICP assessments
- Confirmatory pressure values at diagnosis: Pre-exercise > 15 mmHg; 1-min. post > 30mmHg; or 5-min. post > 20mmHg
- Ages 18-65 years inclusive at study onset.
- Ability to adhere to protocol.
- Botulinum toxin naïve (lower extremity). Others previously treated, > than 6 mos. before study entry.
Who cannot join
- History of Neuromuscular disease, serious soft-tissue injury, fractures, and surgery to the lower limb(s).
- Treatment Groups:
- Diagnosis of comorbid pain conditions, including claudication and/or popliteal artery entrapment syndrome.
- Serious soft tissue injury, fractures, or surgery in the lower limb(s) < than 12 months before study entry.
- Current need for surgery at any level of the lower extremity.
- Treatment with any drug known to interfere with neuromuscular function (e.g., aminoglycoside antibiotics or neuromuscular blocking agents).
Show all 11Show fewer
- Any other medical condition, laboratory, or diagnostic procedure finding that might preclude the administration of aboBoNTA (Dysport®).
- Ongoing infection at the injection sites.
- Diagnosed as either resistant or sensitive to botulinum toxin treatment of any type or to any components of Dysport®
- Cow milk protein allergy.
- Vulnerable patient populations such as adults unable to consent, pregnant women, prisoners, persons who have not obtained the legal age for consent to treatment or procedures
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Emory Sports Medicine-Dunwoody
Atlanta, Georgia, 30338
Emory Hawks Sports Medicine Center
Brookhaven, Georgia, 30329
About this study
Official title: Chronic Exertional Compartment Syndrome (CECS) Evaluated With Needle Manometry and Shear Wave Elastography, and Treated With Ultrasound-Guided AbobotulinumtoxinA
Chronic Exertional Compartment Syndrome (CECS) is a painful condition affecting runners and it is caused by a reversible increase in pressure within a closed compartment in the leg. Currently, to diagnose CECS, a large needle is placed into the muscle to measure pressure, which is invasive and painful. After diagnosis, the gold standard of treatment is surgery, which is also invasive, involves a prolonged return to play, and has a significant number of treatment failures. A growing literature has suggested alternative methods to both diagnosis and treatment that include the use of ultrasound to investigate muscle stiffness with shear wave elastography (SWE), and treatment with botulinum toxin injection into the muscle.
The investigators propose a single-site randomized clinical trial to investigate the use of abobotulinumtoxinA in the treatment of CECS. Researchers also look to develop a non-invasive method for the diagnosis of CECS using SWE. To the researchers' knowledge, this is the first randomized study investigating the medication to treat this cause.
Read more
The study will take place at Emory's outpatient sports medicine clinic. Potential participants will primarily be identified and recruited from the departments of Physical Medicine and Rehabilitation, Orthopedics, Physical Therapy, and Sports medicine as a part of regular clinical care. Participants will be included in the randomized portion of the study if they meet the previously established diagnostic criteria for CECS with compartmental pressure testing.
This would be a landmark study to provide evidence for the use of an abobotulinumtoxinA in the treatment of CECS, leading to the potential avoidance of a surgical procedure. It could also change the means of diagnosis without the use of painful and invasive needle pressure testing that would provide patients and athletes with ease of care.
Read the detailed description
Chronic exertional compartment syndrome (CECS) is an underdiagnosed condition and a cause of lower extremity pain often observed in running athletes. In runners, CECS is characterized by a reversible increase in pressure within an inelastic fascial compartment(s) of the lower extremity, leading to compromised tissue perfusion and subsequent pain and neurologic symptoms. It impacts both pediatric and adult populations. As currently diagnosed and treated, chronic exertional compartment syndrome presents unique challenges. Evaluation of CECS includes a thorough history and physical exam to rule out other causes of exertional leg pain, but the differential diagnosis must remain high on the list. Needle manometry, an invasive and painful procedure, is therefore used to confirm the diagnosis of CECS by measuring intra-compartmental pressure (ICP).
A growing literature, however, positions ultrasound shear wave elastography (SWE) as a viable and attractive alternative to ICP testing as it is both non-invasive and cost-effective. Earlier efforts demonstrated that muscle compartment "hardness" may accurately and noninvasively predict ICP. Building on these, SWE now provides direct measures of related mechanical properties of muscle and compartment, namely, "stiffness", thereby demonstrating promise as a diagnostic tool for CECS. Fasciotomy, currently the most well-accepted treatment approach, still has a significant number of treatment failures, demonstrating the need for additional options. A series of case reports have highlighted the potential merits of botulinum toxin as an alternative non-invasive treatment to surgery. Further, there is a growing consensus that desired BoNT targeting is best achieved through incorporating ultrasound guidance during the injection. The largest case series study to date reported that 15/16 patients with CECS had complete exertional pain relief with aboBoNTA. However, the apparent high dosing also led to a reduction in strength in 11/16 patients - An average of 288 units for the anterior compartment and 180 for the lateral compartment. In sum, the optimal dosage has yet to be determined.
Recently, the research team reported a case of a 39-year-old female runner presenting with lower extremity pain. CECS was confirmed with ICP. In addition, SWE was utilized in diagnosis and management. Briefly, SWE testing showed post-exercise increases in "stiffness" in the right Tibialis Anterior and left Fibularis Brevis relative to baseline measures. To provide perspective, both pre- and post-exercise SWE measures were elevated in this patient compared to two age and sex-matched controls. Following onaBoNTA treatment, further SWE measures revealed a reduction in patient muscle stiffness from the initial pre- and post-exercise treadmill testing, reaching levels comparable to the two asymptomatic age and sex-matched controls by week 6. Collectively, these results support a relationship between changes in intra-compartmental pressure as measured by needle manometry and muscle compartment "stiffness" as measured by SWE, and, as such, a role for SWE in CECS diagnosis and management.
In sum, SWE-based diagnosis coupled with ultrasound-enhanced injection accuracy are introduced to potentially complement and/or replace traditional approaches, which have challenged the diagnosis and management of CECS.
- Conditions
- Compartment Syndrome of Leg
- Being tested
- AbobotulinumtoxinA, Placebo
- Keywords
- Runners, Lower extremity pain, Exertional Compartment Syndrome of the Leg
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AbobotulinumtoxinADrug
Also called Intervention Group
Participants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging.
PlaceboDrug
Also called Control Group
Participants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing.
| Study group | Role | What they receive |
|---|---|---|
| Treatment Group | Experimental | AbobotulinumtoxinA Receives: Drug: AbobotulinumtoxinA |
| Control Group | Placebo comparator | Normal Saline Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Absolute change from baseline in the Visual Analog Scale (VAS) at 3 months following treatment
Participants will be asked to complete questionnaires to evaluate their pain at each follow-up visit. The Visual Analog Scale will be the subjective measurement to evaluate changes in pain scores, with values ranging from 0 (no pain) to 10 (very severe pain). A higher score indicates worse pain
Measured: Baseline and 3 months
Secondary outcomes (9)
Absolute change from baseline in the Visual Analog Scale (VAS) at 5 weeks following treatment
Participants will be asked to complete questionnaires to evaluate their pain at each follow-up visit. The Visual Analog Scale will be the subjective measurement to evaluate changes in pain scores, with values ranging from 0 (no pain) to 10 (very severe pain). A higher score indicates worse pain
Measured: Baseline and 5 weeks
Absolute and Relative change from baseline in the Patient-Reported Outcomes from the University of Wisconsin Running Injury and Recovery Index (UWRI).
The UWRI evaluates the key elements runners use to self-assess running ability during recovery. Scores range from 0 to 36, with higher scores indicating greater running ability.
Measured: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Ultrasound shear wave elastography measure: stiffness in kilopascals (kPa)
Ultrasound shear wave elastography measures (representing stiffness in kilopascals (kPa). A Samsung RS85 Prestige Ultrasound machine will be used. Muscle identification will be performed by trained clinicians in musculoskeletal ultrasound. All participants will be assessed in a supine position, with the foot neutral.
All targets will first be identified via a short axis to the muscle - A transversal view that refers to the transducer being positioned perpendicular to the fibers.
Measured: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Ultrasound shear wave shear wave velocity (m/s) (SWE)
Ultrasound shear wave elastography measures shear wave velocity in m/s (SWE). A Samsung RS85 Prestige Ultrasound machine will be used. Muscle identification will be performed by trained clinicians in musculoskeletal ultrasound. All participants will be assessed in a supine position, with the foot neutral.
All targets will first be identified via a short axis to the muscle - A transversal view that refers to the transducer being positioned perpendicular to the fibers.
Measured: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Single Assessment Numerical Evaluation (SANE)
Participants will be asked how would they rate their affected region of interest today as a percentage of normal? Scoring ranges from 0-100% with 100% being normal.
Measured: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Goal Attainment Scaling (GAS)
GAS consists of several components including current problems, expectations, outcome assessed, pain treatment and review of achieved goals. It has a score based on respect to expectations at baseline (some function vs no function) and at the outcome: was the goal achieved? Yes (a lot more/ a little more/as expected) No (partially achieved, no change, got worse). Scores range from -2 to +2, with positive numbers being positive outcomes.
Measured: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Manual Muscle Testing (MMT)
The patient is instructed to hold the corresponding limb or appropriate body part to be tested at a specific point in its available range of motion, working against gravity or while the practitioner provides opposing manual resistance to determine the grade to assign the muscle. Grades are from 0 to 5 with grade 5 being normal.
Measured: Baseline, 5 weeks and 3 months
Dynamometric Testing (DT) for both legs
Dynamometric Testing (DT) (aka force generation) using Biodex Isokinetic dynamometer systems to measure peak force generated by knee extension, knee flexion, ankle plantarflexion, ankle dorsiflexion, ankle inversion, and ankle eversion
Measured: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Ankle Range of Motion (Ankle ROM) using a goniometer
The joint range of motion is calculated by measuring the angles between the beginning position and the ending position of available motion. Goniometers similar to a carpenter level are called gravity-dependent goniometers, or inclinometers, and are used most often to measure motion in the spine.
Measured: Baseline, 5 weeks and 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2022
- Study start25 Apr 2024
- Primary completion13 Aug 2025
- Study completion13 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Compartment Syndrome of LegStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 3 participants (actual)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- Ipsen
- Responsible party
- Principal investigator, Lee Kneer, Emory University
- Investigators
- Lee Kneer, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05466539
- Sponsor's protocol ID
- STUDY00003790
- Acronym
- CECS
- Status last verified
- Oct 2025
- First submitted
- 5 Jul 2022
- Last updated
- 21 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: The research team will share Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Chronic Exertional Compartment Syndrome (CECS) Evaluated With Needle Manometry and Shear Wave Elastography, and Treated With Ultrasound-Guided AbobotulinumtoxinA
- ClinicalTrials.gov ID
- NCT05466539
- Acronym / sponsor ID
- CECS / STUDY00003790
- Conditions
- Compartment Syndrome of Leg
- Keywords
- Runners, Lower extremity pain, Exertional Compartment Syndrome of the Leg
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3 participants (actual)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- Ipsen
- Study start
- 25 Apr 2024 (actual)
- Primary completion
- 13 Aug 2025 (actual)
- Study completion
- 13 Aug 2025 (actual)
- First posted
- 20 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic Exertional Compartment Syndrome (CECS) is a painful condition affecting runners and it is caused by a reversible increase in pressure within a closed compartment in the leg. Currently, to diagnose CECS, a large needle is placed into the muscle to measure pressure, which is invasive and painful. After diagnosis, the gold standard of treatment is surgery, which is also invasive, involves a prolonged return to play, and has a significant number of treatment failures. A growing literature has suggested alternative methods to both diagnosis and treatment that include the use of ultrasound to investigate muscle stiffness with shear wave elastography (SWE), and treatment with botulinum toxin injection into the muscle.
The investigators propose a single-site randomized clinical trial to investigate the use of abobotulinumtoxinA in the treatment of CECS. Researchers also look to develop a non-invasive method for the diagnosis of CECS using SWE. To the researchers' knowledge, this is the first randomized study investigating the medication to treat this cause.
The study will take place at Emory's outpatient sports medicine clinic. Potential participants will primarily be identified and recruited from the departments of Physical Medicine and Rehabilitation, Orthopedics, Physical Therapy, and Sports medicine as a part of regular clinical care. Participants will be included in the randomized portion of the study if they meet the previously established diagnostic criteria for CECS with compartmental pressure testing.
This would be a landmark study to provide evidence for the use of an abobotulinumtoxinA in the treatment of CECS, leading to the potential avoidance of a surgical procedure. It could also change the means of diagnosis without the use of painful and invasive needle pressure testing that would provide patients and athletes with ease of care.
Detailed description
Chronic exertional compartment syndrome (CECS) is an underdiagnosed condition and a cause of lower extremity pain often observed in running athletes. In runners, CECS is characterized by a reversible increase in pressure within an inelastic fascial compartment(s) of the lower extremity, leading to compromised tissue perfusion and subsequent pain and neurologic symptoms. It impacts both pediatric and adult populations. As currently diagnosed and treated, chronic exertional compartment syndrome presents unique challenges. Evaluation of CECS includes a thorough history and physical exam to rule out other causes of exertional leg pain, but the differential diagnosis must remain high on the list. Needle manometry, an invasive and painful procedure, is therefore used to confirm the diagnosis of CECS by measuring intra-compartmental pressure (ICP).
A growing literature, however, positions ultrasound shear wave elastography (SWE) as a viable and attractive alternative to ICP testing as it is both non-invasive and cost-effective. Earlier efforts demonstrated that muscle compartment "hardness" may accurately and noninvasively predict ICP. Building on these, SWE now provides direct measures of related mechanical properties of muscle and compartment, namely, "stiffness", thereby demonstrating promise as a diagnostic tool for CECS. Fasciotomy, currently the most well-accepted treatment approach, still has a significant number of treatment failures, demonstrating the need for additional options. A series of case reports have highlighted the potential merits of botulinum toxin as an alternative non-invasive treatment to surgery. Further, there is a growing consensus that desired BoNT targeting is best achieved through incorporating ultrasound guidance during the injection. The largest case series study to date reported that 15/16 patients with CECS had complete exertional pain relief with aboBoNTA. However, the apparent high dosing also led to a reduction in strength in 11/16 patients - An average of 288 units for the anterior compartment and 180 for the lateral compartment. In sum, the optimal dosage has yet to be determined.
Recently, the research team reported a case of a 39-year-old female runner presenting with lower extremity pain. CECS was confirmed with ICP. In addition, SWE was utilized in diagnosis and management. Briefly, SWE testing showed post-exercise increases in "stiffness" in the right Tibialis Anterior and left Fibularis Brevis relative to baseline measures. To provide perspective, both pre- and post-exercise SWE measures were elevated in this patient compared to two age and sex-matched controls. Following onaBoNTA treatment, further SWE measures revealed a reduction in patient muscle stiffness from the initial pre- and post-exercise treadmill testing, reaching levels comparable to the two asymptomatic age and sex-matched controls by week 6. Collectively, these results support a relationship between changes in intra-compartmental pressure as measured by needle manometry and muscle compartment "stiffness" as measured by SWE, and, as such, a role for SWE in CECS diagnosis and management.
In sum, SWE-based diagnosis coupled with ultrasound-enhanced injection accuracy are introduced to potentially complement and/or replace traditional approaches, which have challenged the diagnosis and management of CECS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment Group | Experimental | Drug: AbobotulinumtoxinAAbobotulinumtoxinA |
| Control Group | Placebo comparator | Drug: PlaceboNormal Saline |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adult male and female runners aged 18-65 years
- Group providing normative values for SWE and needle manometry - ICP assessments
- Confirmatory pressure values at diagnosis: Pre-exercise > 15 mmHg; 1-min. post > 30mmHg; or 5-min. post > 20mmHg
- Ages 18-65 years inclusive at study onset.
- Ability to adhere to protocol.
Key exclusion criteria (11 listed)
- History of Neuromuscular disease, serious soft-tissue injury, fractures, and surgery to the lower limb(s).
- Diagnosis of comorbid pain conditions, including claudication and/or popliteal artery entrapment syndrome.
- Serious soft tissue injury, fractures, or surgery in the lower limb(s) < than 12 months before study entry.
- Current need for surgery at any level of the lower extremity.
- Treatment with any drug known to interfere with neuromuscular function (e.g., aminoglycoside antibiotics or neuromuscular blocking agents).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AbobotulinumtoxinAAlso: Intervention GroupParticipants randomized to receive aboBoNTA will receive a maximum of 200 units of aboBoNTA distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior (60 units), Extensor Digitorum Longus (20) and Extensor Hallucis Longus (20); (L) Fibularis Brevis (50) and Fibularis Longus (50). Tibialis Anterior (60U); Extensor Digitorum Longus (20); Extensor Halluces Longus (20); Fibularis Brevis (50), and; Fibularis longus (50). Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing and SWE imaging. | Drug | Treatment Group |
| PlaceboAlso: Control GroupParticipants randomized into the normal saline group will receive injections distributed across the following muscles: Targeted muscles will be selected from the Anterior (A) and Lateral (L) Compartments. They include (A) Tibialis Anterior, Extensor Digitorum Longus, and Extensor Hallucis Longus; (L) Fibularis Brevis and Fibularis Longus. Tibialis Anterior; Extensor Digitorum Longus; Extensor Halluces Longus; Fibularis Brevis, and; Fibularis longus. Treatment distribution across targeted muscles will be based on clinical presentation including muscle compartment(s) involvement as determined by ICP testing. | Drug | Control Group |
Primary outcome
Absolute change from baseline in the Visual Analog Scale (VAS) at 3 months following treatment
Time frame: Baseline and 3 months
Participants will be asked to complete questionnaires to evaluate their pain at each follow-up visit. The Visual Analog Scale will be the subjective measurement to evaluate changes in pain scores, with values ranging from 0 (no pain) to 10 (very severe pain). A higher score indicates worse pain
9 secondary outcomes
Absolute change from baseline in the Visual Analog Scale (VAS) at 5 weeks following treatment
Time frame: Baseline and 5 weeks
Absolute and Relative change from baseline in the Patient-Reported Outcomes from the University of Wisconsin Running Injury and Recovery Index (UWRI).
Time frame: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Ultrasound shear wave elastography measure: stiffness in kilopascals (kPa)
Time frame: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Ultrasound shear wave shear wave velocity (m/s) (SWE)
Time frame: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Single Assessment Numerical Evaluation (SANE)
Time frame: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Goal Attainment Scaling (GAS)
Time frame: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Manual Muscle Testing (MMT)
Time frame: Baseline, 5 weeks and 3 months
Dynamometric Testing (DT) for both legs
Time frame: Baseline, 5 weeks and 3 months
Absolute and Relative change from baseline in the Ankle Range of Motion (Ankle ROM) using a goniometer
Time frame: Baseline, 5 weeks and 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2025.
- Individual participant dataSharing planned: Yes. The research team will share Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)
Related trials for Compartment Syndrome of Leg
Recruiting
Physiotherapy or Fasciotomy as Treatment for Chronic Exertional Compartment Syndrome in the Lower Leg?
Compartment Syndrome Nontraumatic Lower Leg
Recruiting
Treatment of Lower Leg Anterolateral Chronic Exertional Compartment Syndrome With Intra-muscular Botulinum Injections.
Chronic Exertional Compartment Syndrome
Recruiting
Continuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients
Compartment Syndrome of Leg, Extracorporeal Membrane Oxygenation Complication
Recruiting
Evaluation of the Diagnostic and Therapeutic Value of Tissue Ultrafiltration in Patients at Risk of Acute Compartment Syndrome (ACS)
Acute Compartment Syndrome, Fracture, Bone
RecruitingObservational study
Can Near-Infrared Spectroscopy (NIRS) or Intramuscular Glucose Levels Detect Impaired Leg Compartment' Perfusion?
Compartment Syndromes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lee Kneer principal investigator
Emory University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing AbobotulinumtoxinA in people with Compartment Syndrome of Leg, run by Emory University at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Absolute change from baseline in the Visual Analog Scale (VAS) at 3 months following treatment (time frame: Baseline and 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2025.